Strength in the pharmaceutical major’s oncology business offset weak China sales, but the company has warned of a potential ...

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this ...

Japan's Toyota Motor is expected to post its second consecutive quarterly profit drop when it reports third-quarter earnings ...

Chipotle Mexican Grill said on Tuesday that if President Donald Trump's proposed tariffs on Mexico go into full effect, the ...

International Business Machines Corp. gave a stronger-than-expected revenue growth outlook for the coming years led by the ...

The Danish pharmaceutical company expects sales growth to slow this year as capacity constraints, intensifying competition ...

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...

New data from the accounting platform Xero should give American entrepreneurs one more reason to be optimistic about 2025.

Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

Veralto Corporation delivered all-time high annual sales of $5.2 billion in 2024, with 3.7% core sales growth and an adjusted earnings per share increase of 11% to $3.54. Free cash flow generation ...

Kenvue posted mixed Q4 earnings, with in-line EPS but revenue below estimates, driven by challenges in its Skin Health and ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...